Edition:
India

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

55.50USD
15 Dec 2017
Change (% chg)

$0.77 (+1.41%)
Prev Close
$54.73
Open
$55.03
Day's High
$55.56
Day's Low
$54.85
Volume
7,626,181
Avg. Vol
1,612,878
52-wk High
$56.68
52-wk Low
$37.90

Chart for

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.57
Market Cap(Mil.): $95,559.38
Shares Outstanding(Mil.): 1,737.44
Dividend: 0.26
Yield (%): 1.93

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Abbott Increases Quarterly Dividend To 28 Cents Per Share

* ABBOTT LABORATORIES - INCREASED COMPANY'S QUARTERLY COMMON DIVIDEND TO 28 CENTS PER SHARE FROM 26.5 CENTS PER SHARE Source text for Eikon: Further company coverage:

15 Dec 2017

BRIEF-Abbott's mitraclip approved as first transcatheter mitral valve repair device in Japan

* Abbott's mitraclip approved as first transcatheter mitral valve repair device in Japan Source text for Eikon: Further company coverage:

06 Nov 2017

Fitch Withdraws Abbott Laboratories' Ratings

(The following statement was released by the rating agency) CHICAGO, November 02 (Fitch) Fitch Ratings has chosen to withdraw the ratings of Abbott Laboratories and St. Jude Medical, Inc. for commercial reasons. RATING SENSITIVITIES Ratings sensitivities are no longer relevant given today's withdrawal. FULL LIST OF RATING ACTIONS Fitch has affirmed and subsequently withdrawn the following ratings. Abbott Laboratories --Long-Term Issuer Default Rating 'BBB', Outlook Stable; --Senior unsecured ban

03 Nov 2017

BRIEF-Abbott gets FDA clearance for its Alinity ci-series instruments

* Abbott announces FDA clearance for its Alinity ci-series next-generation diagnostic systems

31 Oct 2017

BRIEF-Abbott says ‍secured FDA clearance for confirm Rx Insertable Cardiac Monitor​

* Abbott - ‍secured FDA clearance for confirm Rx Insertable Cardiac Monitor​ Source text for Eikon: Further company coverage:

23 Oct 2017

Abbott's recent deals, medical device pipeline to fuel growth

Abbott Laboratories' quarterly results beat estimates and the company raised the top end of its full-year earnings forecast range on Wednesday, as a string of recent deals and medical device approvals help spur growth in its largest unit.

18 Oct 2017

BRIEF-Abbott CFO says Alere is expected to contribute around $475 mln to reported sales this year

* Abbott CFO says Alere, is expected to contribute around $475 million to reported sales, and forecast a neutral impact on adjusted earnings per share this year - Conf Call

18 Oct 2017

UPDATE 3-Abbott's recent deals, medical device pipeline to fuel growth

* Shares up 2.8 pct to record high (Adds conference call details, updates shares)

18 Oct 2017

BRIEF-Abbott Q3 adjusted EPS $0.66 from continuing operations

* Sees FY 2017 gaap earnings per share $0.97 to $0.99 from continuing operations

18 Oct 2017

Abbott Labs posts quarterly profit vs. year-ago loss

Oct 18 Diversified healthcare company Abbott Laboratories on Wednesday reported a quarterly profit compared with a loss in the year-ago quarter, helped by strong sales in its medical devices and generics businesses.

18 Oct 2017

Competitors

Earnings vs. Estimates